Data / Drug companies / Programmed Death Receptor-1 Blocking Antibody
Programmed Death Receptor-1 Blocking Antibody drugs: 11 drugs from 7 companies in the FDA NDC directory
Programmed Death Receptor-1 Blocking Antibody is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 18 products in this class from 7 companies, covering 11 drugs by generic name. The main marketing category is biologics (BLA), and the newest product started marketing on July 13, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 7Companies
- 18Products
- 11Drugs by generic name
Drugs in the Programmed Death Receptor-1 Blocking Antibody class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Nivolumab | 4 | 1 |
| Atezolizumab | 2 | 1 |
| Nivolumab and hyaluronidase-nvhy | 2 | 1 |
| Pembrolizumab and berahyaluronidase alfa-pmph | 2 | 1 |
| Tislelizumab-jsgr | 2 | 1 |
| Atezolizumab and hyaluronidase-tqjs | 1 | 1 |
| Dostarlimab | 1 | 1 |
| Nivolumab and relatlimab-rmbw | 1 | 1 |
| Pembrolizumab | 1 | 1 |
| Retifanlimab-dlwr | 1 | 1 |
| Toripalimab-tpzi | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 7 | injection; injection, solution | Biologics (BLA) | January 2, 2025 |
| Genentech, Inc. | 3 | injection, solution; injection | Biologics (BLA) | September 12, 2024 |
| Merck Sharp & Dohme LLC | 3 | injection, solution | Biologics (BLA) | September 19, 2025 |
| BeOne Medicines USA, Inc. | 2 | injection, solution, concentrate | Biologics (BLA) | July 13, 2026 |
| Coherus Oncology, Inc. | 1 | injection | Biologics (BLA) | October 27, 2023 |
| GlaxoSmithKline LLC | 1 | injection | Biologics (BLA) | April 22, 2021 |
| Incyte Corporation | 1 | injection | Biologics (BLA) | March 22, 2023 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 9 | 50% |
| Injection, solution | 7 | 38.9% |
| Injection, solution, concentrate | 2 | 11.1% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.